Question: You are an expert researcher providing comprehensive, well-cited information.

Provide detailed information focusing on: 1. Key concepts and definitions with current understanding 2. Recent developments and latest research (prioritize 2023-2024 sources) 3. Current applications and real-world implementations 4. Expert opinions and analysis from authoritative sources 5. Relevant statistics and data from recent studies

Format as a comprehensive research report with proper citations. Include URLs and publication dates where available. Always prioritize recent, authoritative sources and provide specific citations for all major claims.

Disease Characteristics Research Template

Target Disease

• Disease Name: Marchiafava-Bignami Disease
• MONDO ID: (if available)
• Category: Neurological Disorder

Research Objectives

Please provide a comprehensive research report on Marchiafava-Bignami Disease covering all of the disease characteristics listed below. This report will be used to populate a disease knowledge base entry. Be thorough and cite primary literature (PMID preferred) for all claims.

For each section, suggested databases/resources are listed. These are the first places you should search for information on each topic.

1. Disease Information

Search first: OMIM, Orphanet, ICD-10/ICD-11, MeSH, PubMed

• What is the disease? Provide a concise overview.
• What are the key identifiers? (OMIM, Orphanet, ICD-10/ICD-11, MeSH, Mondo)
• What are the common synonyms and alternative names?
• Is the information derived from individual patients (e.g., EHR) or aggregated disease-level resources?

2. Etiology

• Disease Causal Factors: What are the primary causes? (genetic, environmental, infectious, mechanistic)
• Risk Factors:

  Search first: PubMed, Cochrane Library, UpToDate, clinical guidelines, ClinVar, ClinGen, GWAS Catalog, PheGenI, CTD, CDC, WHO, epidemiological databases

• Genetic risk factors (causal variants, susceptibility loci, modifier genes)
• Environmental risk factors (toxins, lifestyle, occupational exposures, age, sex, family history)
• Protective Factors:

  Search first: PubMed, Cochrane Library, clinical trial databases, GWAS Catalog, gnomAD, WHO, CDC, nutrition databases

• Genetic protective factors (protective variants, modifier alleles)
• Environmental protective factors (diet, lifestyle, exposures that reduce risk)
• Gene-Environment Interactions: How do genetic and environmental factors interact to influence disease?

  Search first: CTD, PubMed, PheGenI, GxE databases

3. Phenotypes

Search first: HPO (Human Phenotype Ontology), OMIM, Orphanet, PubMed, clinicaltrials.gov, MedDRA, SNOMED CT, DECIPHER, LOINC

For each phenotype, provide: - Phenotype type: symptoms, clinical signs, physical manifestations, behavioral changes, or laboratory abnormalities

For symptoms/signs: HPO, OMIM, Orphanet, PubMed For behavioral changes: HPO, DSM, RDoC (Research Domain Criteria), PubMed For laboratory abnormalities: LOINC, SNOMED CT, LabTests Online, PubMed - Phenotype characteristics: Search first: OMIM, Orphanet, HPO, PubMed - Age of symptom onset (neonatal, childhood, adult-onset, late-onset) - Symptom severity (mild, moderate, severe, variable) - Symptom progression (stable, progressive, episodic, fluctuating) - Frequency among affected individuals (percentage or qualitative) - Quality of life impact: Effects on daily functioning and well-being (per-phenotype when possible) Search first: EQ-5D database, SF-36, WHO QOL databases, PubMed - Suggest HPO (Human Phenotype Ontology) terms for each phenotype

4. Genetic/Molecular Information

• Causal Genes: Gene mutations or chromosomal abnormalities responsible for disease (gene symbols, OMIM IDs)

  Search first: OMIM, ClinVar, HGMD, Ensembl, NCBI Gene

• Pathogenic Variants:
• Affected genes (gene symbols, HGNC IDs) > Search first: OMIM, NCBI Gene, Ensembl, HGNC, UniProt, GeneCards
• Variant classification (pathogenic, likely pathogenic, VUS per ACMG/AMP guidelines) > Search first: ClinVar, ClinGen, ACMG/AMP guidelines, VarSome
• Variant type/class (missense, frameshift, nonsense, splice-site, structural)
• Allele frequency in population databases > Search first: gnomAD, 1000 Genomes, ExAC, TOPMed, dbSNP
• Somatic vs germline origin > Search first: COSMIC (somatic), ClinVar, ICGC, TCGA
• Functional consequences (loss of function, gain of function, dominant negative)
• Modifier Genes: Genes that modify disease severity or expression
• Epigenetic Information: DNA methylation, histone modifications, chromatin changes affecting disease

  Search first: ENCODE, Roadmap Epigenomics, MethBase, DiseaseMeth

• Chromosomal Abnormalities: Large-scale genetic changes (aneuploidy, translocations, inversions)

  Search first: DECIPHER, ClinVar, ECARUCA, UCSC Genome Browser

5. Environmental Information

• Environmental Factors: Non-genetic contributing factors (toxins, radiation, pollution, occupational exposure)

  Search first: CTD (Comparative Toxicogenomics Database), TOXNET, PubMed, EPA databases

• Lifestyle Factors: Behavioral factors (smoking, diet, exercise, alcohol consumption)

  Search first: CDC databases, WHO, PubMed, NHANES

• Infectious Agents: If applicable, pathogens causing or triggering disease (bacteria, viruses, fungi, parasites)

  Search first: NCBI Taxonomy, ViPR, BV-BRC, MicrobeDB, GIDEON

6. Mechanism / Pathophysiology

• Molecular Pathways: Specific signaling cascades or biochemical pathways involved (Wnt, MAPK, mTOR, PI3K-AKT, etc.)

  Search first: KEGG, Reactome, WikiPathways, PathBank, BioCyc

• Cellular Processes: Cell-level mechanisms (apoptosis, autophagy, cell cycle dysregulation, inflammation, etc.)

  Search first: Gene Ontology (GO), Reactome, KEGG, PubMed

• Protein Dysfunction: How protein structure or function is altered (misfolding, aggregation, loss of function, gain of function)

  Search first: UniProt, PDB (Protein Data Bank), InterPro, Pfam, AlphaFold

• Metabolic Changes: Alterations in metabolic processes (energy metabolism, lipid metabolism, amino acid metabolism)

  Search first: KEGG, BioCyc, HMDB (Human Metabolome Database), BRENDA

• Immune System Involvement: Role of immune response (autoimmunity, immunodeficiency, chronic inflammation)

  Search first: ImmPort, Immunome Database, IEDB, Gene Ontology

• Tissue Damage Mechanisms: How tissues/ are injured (oxidative stress, ischemia, fibrosis, necrosis)

  Search first: PubMed, Gene Ontology, Reactome

• Biochemical Abnormalities: Specific molecular defects (enzyme deficiencies, receptor dysfunction, ion channel defects)

  Search first: BRENDA, UniProt, KEGG, OMIM, PubMed

• Epigenetic Changes: DNA methylation, histone modifications affecting gene expression in disease

  Search first: ENCODE, Roadmap Epigenomics, MethBase, DiseaseMeth

• Molecular Profiling (if available):
• Transcriptomics/gene expression changes > Search first: GEO (Gene Expression Omnibus), ArrayExpress, GTEx, Human Cell Atlas, SRA
• Proteomics findings > Search first: PRIDE, ProteomeXchange, Human Protein Atlas, STRING, BioGRID
• Metabolomics signatures > Search first: MetaboLights, Metabolomics Workbench, HMDB, METLIN
• Lipidomics alterations > Search first: LIPID MAPS, SwissLipids, LipidHome, Metabolomics Workbench
• Genomic structural features > Search first: UCSC Genome Browser, Ensembl, NCBI, dbVar, DGV
• Advanced Technologies (if applicable):
• Single-cell analysis findings (cell-type specific mechanisms, cellular heterogeneity) > Search first: Human Cell Atlas, Single Cell Portal, GEO, CELLxGENE
• Spatial transcriptomics findings > Search first: GEO, Spatial Research, Vizgen, 10x Genomics data
• Multi-omics integration results > Search first: TCGA, ICGC, cBioPortal, LinkedOmics, PubMed
• Functional genomics screens (CRISPR, RNAi) > Search first: DepMap, GenomeRNAi, PubMed, BioGRID ORCS

For each mechanism, describe: - The causal chain from initial trigger to clinical manifestation - Which mechanisms are upstream vs downstream - What cell types and biological processes are involved - Suggest GO terms for biological processes and CL terms for cell types

7. Anatomical Structures Affected

• Organ Level:
• Primary organs directly affected
• Secondary organ involvement (complications, secondary effects)
• Body systems involved (cardiovascular, nervous, digestive, respiratory, endocrine, etc.)

  Search first: Uberon, FMA (Foundational Model of Anatomy), OMIM, HPO, ICD-11, MeSH, SNOMED CT

• Tissue and Cell Level:
• Specific tissue types affected (epithelial, connective, muscle, nervous)
• Specific cell populations targeted (with Cell Ontology terms)

  Search first: Uberon, Human Protein Atlas, Cell Ontology, Human Cell Atlas, CellMarker, PanglaoDB

• Subcellular Level:
• Cellular compartments involved (mitochondria, nucleus, ER, lysosomes) (with GO Cellular Component terms)

  Search first: Gene Ontology (Cellular Component), UniProt, Human Protein Atlas

• Localization:
• Specific anatomical sites (with UBERON terms) > Search first: FMA, Uberon, NeuroNames (for brain), SNOMED CT
• Lateralization (unilateral, bilateral, asymmetric) > Search first: HPO, clinical literature, imaging databases

8. Temporal Development

• Onset:
• Typical age of onset (congenital, pediatric, adult, geriatric)
• Onset pattern (acute, subacute, chronic, insidious)

  Search first: OMIM, Orphanet, HPO, PubMed

• Progression:
• Disease stages (early, intermediate, advanced, end-stage) > Search first: Cancer Staging Manual (AJCC), WHO classifications, PubMed
• Progression rate (rapid, slow, variable)
• Disease course pattern (episodic, relapsing-remitting, progressive, stable)
• Disease duration (self-limited, chronic lifelong)

  Search first: Disease registries, longitudinal cohort databases, natural history studies, PubMed, Orphanet, OMIM

• Patterns:
• Remission patterns (spontaneous, treatment-induced) > Search first: Clinical trial databases, disease registries, PubMed
• Critical periods (time windows of vulnerability or opportunity for intervention) > Search first: PubMed, developmental biology databases, clinical guidelines

9. Inheritance and Population

• Epidemiology:
• Prevalence (cases per 100,000 at given time)
• Incidence (new cases per 100,000 per year)

  Search first: Orphanet, CDC, WHO, GBD (Global Burden of Disease), national registries, SEER, disease registries

• For Genetic Etiology:
• Inheritance pattern (AD, AR, X-linked, mitochondrial, multifactorial, polygenic) > Search first: OMIM, Orphanet, ClinVar, GTR (Genetic Testing Registry)
• Penetrance (complete, incomplete, age-dependent) > Search first: ClinVar, OMIM, PubMed, ClinGen
• Expressivity (variable, consistent) > Search first: OMIM, ClinVar, PubMed
• Genetic anticipation (increasing severity in successive generations) > Search first: OMIM, PubMed (especially for repeat expansion disorders)
• Germline mosaicism > Search first: ClinVar, OMIM, genetic counseling literature, PubMed
• Founder effects (population-specific mutations) > Search first: gnomAD, population genetics databases, PubMed
• Consanguinity role > Search first: OMIM, population studies, genetic counseling resources
• Carrier frequency > Search first: gnomAD, carrier screening databases, GeneReviews, GTR
• Population Demographics:
• Affected populations (ethnic or demographic groups with higher prevalence) > Search first: gnomAD, 1000 Genomes, PAGE Study, PubMed, population registries
• Geographic distribution (endemic areas, regional variation) > Search first: WHO, CDC, GBD, Orphanet, geographic epidemiology databases
• Geographic distribution of specific variants
• Sex ratio (male:female) > Search first: Disease registries, OMIM, PubMed, epidemiological databases
• Age distribution of affected individuals > Search first: CDC, disease registries, SEER, Orphanet

10. Diagnostics

• Clinical Tests:
• Laboratory tests (blood, urine, tissue chemistry, specific enzyme assays) > Search first: LOINC, LabTests Online, PubMed
• Biomarkers (proteins, metabolites, genetic markers, circulating biomarkers) > Search first: FDA Biomarker List, BEST (Biomarkers, EndpointS, and other Tools), PubMed
• Imaging studies (X-ray, CT, MRI, PET, ultrasound) > Search first: RadLex, DICOM, Radiopaedia, imaging databases
• Functional tests (pulmonary function, cardiac stress tests) > Search first: LOINC, clinical guidelines, PubMed
• Electrophysiology (EEG, EMG, ECG, nerve conduction studies) > Search first: LOINC, clinical neurophysiology databases, PubMed
• Biopsy findings (histopathology, immunohistochemistry) > Search first: SNOMED CT, College of American Pathologists resources, PubMed
• Pathology findings (microscopic examination) > Search first: SNOMED CT, Digital Pathology databases, PubMed
• Genetic Testing:

  Search first: GTR (Genetic Testing Registry), GeneReviews, ClinGen

• Overview of recommended genetic testing approach
• Whole genome sequencing (WGS) utility > Search first: GTR, ClinVar, GEL (Genomics England), gnomAD
• Whole exome sequencing (WES) utility > Search first: GTR, ClinVar, OMIM, GeneMatcher
• Gene panels (which panels, which genes) > Search first: GTR, ClinVar, laboratory-specific databases
• Single gene testing > Search first: GTR, ClinVar, OMIM, GeneReviews
• Chromosomal microarray (CMA) > Search first: DECIPHER, ClinVar, dbVar, ECARUCA
• Karyotyping > Search first: Chromosome Abnormality Database, ClinVar, cytogenetics resources
• FISH > Search first: ClinVar, cytogenetics databases, PubMed
• Mitochondrial DNA testing > Search first: MITOMAP, MSeqDR, ClinVar, GTR
• Repeat expansion testing > Search first: GTR, ClinVar, repeat expansion databases, PubMed
• Omics-Based Diagnostics (if applicable):
• RNA sequencing / transcriptomics > Search first: GEO, ArrayExpress, GTEx, RNA-seq databases
• Proteomics > Search first: PRIDE, ProteomeXchange, FDA Biomarker database
• Metabolomics > Search first: MetaboLights, Metabolomics Workbench, HMDB
• Epigenomics > Search first: GEO, ENCODE, Roadmap Epigenomics, MethBase
• Liquid biopsy > Search first: COSMIC, ClinVar, liquid biopsy databases, PubMed
• Clinical Criteria:
• Standardized diagnostic criteria (DSM, ICD, society guidelines) > Search first: DSM-5, ICD-11, clinical society guidelines, UpToDate
• Differential diagnosis (other conditions to rule out, with distinguishing features) > Search first: DynaMed, UpToDate, clinical decision support systems
• Screening:
• Screening methods for asymptomatic individuals (newborn screening, carrier screening, cascade screening) > Search first: ACMG recommendations, CDC newborn screening, GTR

11. Outcome/Prognosis

• Survival and Mortality:
• Survival rate (5-year, 10-year, overall) > Search first: SEER, cancer registries, disease-specific registries, PubMed
• Life expectancy (with and without treatment if applicable) > Search first: Orphanet, disease registries, actuarial databases, PubMed
• Mortality rate > Search first: CDC, WHO, GBD, national mortality databases
• Disease-specific mortality (deaths directly attributable to disease) > Search first: Disease registries, CDC Wonder, GBD, PubMed
• Morbidity and Function:
• Morbidity (disease-related disability and health impacts) > Search first: GBD, WHO, disability databases, PubMed
• Disability outcomes (long-term functional impairments) > Search first: ICF (International Classification of Functioning), disability registries
• Quality of life measures (EQ-5D, SF-36, PROMIS, disease-specific tools) > Search first: EQ-5D database, SF-36, PROMIS, PubMed
• Disease Course:
• Complications (secondary problems: infections, organ failure, etc.) > Search first: ICD codes, disease registries, clinical databases, PubMed
• Recovery potential (likelihood and extent of recovery, with vs without treatment) > Search first: Natural history studies, rehabilitation databases, PubMed
• Prediction:
• Prognostic factors (age, disease severity, biomarkers, treatment response) > Search first: Prognostic models databases, clinical calculators, PubMed
• Prognostic biomarkers (molecular markers predicting disease course) > Search first: FDA Biomarker database, PubMed, cancer prognostic databases

12. Treatment

• Pharmacotherapy:
• Pharmacological treatments (drug names, drug classes, mechanisms of action) > Search first: DrugBank, RxNorm, ATC classification, DailyMed, FDA databases
• Pharmacogenomics (how genetic variants affect drug metabolism, efficacy, toxicity) > Search first: PharmGKB, CPIC (Clinical Pharmacogenetics), FDA Table of PGx Biomarkers
• Advanced Therapeutics:
• Gene therapy (viral vectors, CRISPR, gene replacement, gene editing) > Search first: ClinicalTrials.gov, FDA gene therapy database, ASGCT resources
• Cell therapy (stem cell transplant, CAR-T, cellular therapeutics) > Search first: ClinicalTrials.gov, FDA cell therapy database, FACT standards
• RNA-based therapies (ASOs, siRNA, mRNA therapies) > Search first: ClinicalTrials.gov, FDA approvals, PubMed
• Targeted therapies (treatments directed at specific molecular targets) > Search first: My Cancer Genome, OncoKB, ClinicalTrials.gov, FDA approvals
• Immunotherapies (checkpoint inhibitors, monoclonal antibodies) > Search first: Cancer Immunotherapy Database, FDA approvals, ClinicalTrials.gov
• Surgical and Interventional:
• Surgical interventions (types of surgery, timing, outcomes) > Search first: CPT codes, surgical registries, clinical guidelines, PubMed
• Supportive and Rehabilitative:
• Supportive care (symptom management, pain control, nutrition) > Search first: Clinical guidelines, Cochrane Library, PubMed
• Rehabilitation (physical therapy, occupational therapy, speech therapy) > Search first: Rehabilitation medicine databases, clinical guidelines, PubMed
• Experimental:
• Experimental treatments in clinical trials (with NCT identifiers if available) > Search first: ClinicalTrials.gov, EU Clinical Trials Register, WHO ICTRP
• Treatment Outcomes:
• Treatment response rates > Search first: Clinical trial databases, FDA reviews, systematic reviews, PubMed
• Side effects and adverse events > Search first: FDA Adverse Event Reporting System (FAERS), MedWatch, PubMed
• Treatment Strategy:
• Treatment algorithms (clinical pathways, decision trees) > Search first: Clinical practice guidelines, NCCN Guidelines, UpToDate
• Combination therapies > Search first: ClinicalTrials.gov, treatment guidelines, PubMed
• Personalized medicine approaches (genotype-guided treatment) > Search first: My Cancer Genome, CIViC, PharmGKB, precision medicine databases

For each treatment, suggest MAXO (Medical Action Ontology) terms where applicable.

13. Prevention

• Prevention Levels:
• Primary prevention (preventing disease occurrence: vaccination, risk factor modification) > Search first: CDC, WHO, USPSTF recommendations, Cochrane Library
• Secondary prevention (early detection and treatment: screening programs, early intervention) > Search first: USPSTF, CDC screening guidelines, WHO
• Tertiary prevention (preventing complications in those with disease) > Search first: Clinical guidelines, disease management protocols, PubMed
• Immunization: Vaccine strategies (if applicable)

  Search first: CDC vaccine schedules, WHO immunization, FDA vaccine database

• Screening and Early Detection:
• Screening programs (population-based: newborn screening, cancer screening) > Search first: CDC screening programs, USPSTF, cancer screening databases
• Genetic screening (carrier screening, preimplantation genetic diagnosis, prenatal testing) > Search first: ACMG recommendations, ACOG guidelines, GTR
• Risk stratification (identifying high-risk individuals for targeted prevention) > Search first: Risk prediction models, clinical calculators, PubMed
• Behavioral Interventions: Lifestyle modifications to reduce risk

  Search first: CDC, WHO, behavioral intervention databases, Cochrane Library

• Counseling: Genetic counseling (risk assessment, family planning guidance)

  Search first: NSGC resources, ACMG guidelines, GeneReviews

• Public Health:
• Public health interventions (sanitation, vector control, health education) > Search first: CDC, WHO, public health databases, PubMed
• Environmental interventions (reducing environmental risk factors) > Search first: EPA databases, WHO environmental health, PubMed
• Prophylaxis: Preventive medications or procedures

  Search first: Clinical guidelines, FDA approvals, PubMed

14. Other Species / Natural Disease

• Taxonomy: Species affected (with NCBI Taxon identifiers)

  Search first: NCBI Taxonomy

• Breed: Specific breeds affected (with VBO identifiers if applicable)

  Search first: VBO (Vertebrate Breed Ontology)

• Gene: Orthologous genes in other species (with NCBI Gene IDs)

  Search first: NCBI Gene

• Natural Disease:
• Naturally occurring disease in other species (companion animals, wildlife) > Search first: OMIA (Online Mendelian Inheritance in Animals), VetCompass, PubMed
• Veterinary relevance and importance in animal health > Search first: OMIA, veterinary databases, PubMed
• Comparative Biology:
• Comparative pathology (similarities and differences across species) > Search first: OMIA, comparative pathology databases, PubMed
• Evolutionary conservation of disease mechanisms > Search first: HomoloGene, OrthoMCL, Alliance of Genome Resources
• Transmission (if applicable):
• Zoonotic potential > Search first: CDC zoonotic diseases, WHO zoonoses, GIDEON
• Cross-species susceptibility > Search first: NCBI Taxonomy, veterinary databases, PubMed

15. Model Organisms

• Model Types:
• Model organism type (mammalian, invertebrate, cellular, in vitro) > Search first: Alliance of Genome Resources, model organism databases
• Specific model systems (mouse, rat, zebrafish, Drosophila, C. elegans, yeast, cell lines, organoids, iPSCs) > Search first: MGI, RGD, ZFIN, FlyBase, WormBase, SGD, ATCC, Cellosaurus
• Induced models (drug treatment, surgical intervention, environmental manipulation) > Search first: MGI, model organism databases, PubMed
• Genetic Models:
• Types available (knockout, knock-in, transgenic, conditional, humanized) > Search first: MGI, IMPC, KOMP, EuMMCR, IMSR
• Model Characteristics:
• Phenotype recapitulation (how well model reproduces human disease features) > Search first: Model organism databases, comparative studies, PubMed
• Model limitations (aspects of human disease not captured) > Search first: Model organism databases, PubMed, review articles
• Applications:
• Research applications (what aspects of disease can be studied) > Search first: Model organism databases, PubMed
• Resources:
• Model databases > Search first: MGI, RGD, ZFIN, FlyBase, WormBase, IMSR, EMMA, MMRRC

Citation Requirements

• Cite primary literature (PMID preferred) for all mechanistic and clinical claims
• Prioritize recent reviews and landmark papers
• Include direct quotes from abstracts where possible to support key statements
• Distinguish evidence source types: human clinical, model organism, in vitro, computational

Output Format

Structure your response as a comprehensive narrative organized by the sections above. For each section, provide: - Factual content with specific details (numbers, percentages, gene names, variant nomenclature) - Ontology term suggestions (HPO, GO, CL, UBERON, CHEBI, MAXO, MONDO) where applicable - Evidence citations with PMIDs - Direct quotes from abstracts to support key claims - Clear indication when information is not available or not applicable for this disease

This report will be used to populate a disease knowledge base entry with: - Pathophysiology descriptions with causal chains - Gene/protein annotations (HGNC, GO terms) - Phenotype associations (HP terms) with frequencies - Cell type involvement (CL terms) - Anatomical locations (UBERON terms) - Chemical entities (CHEBI terms) - Treatment annotations (MAXO terms) - Evidence items with PMIDs and exact abstract quotes - Epidemiology, prognosis, diagnostic, and prevention information - Animal model descriptions with phenotype recapitulation details

Comprehensive Disease Characteristics Report: Marchiafava–Bignami Disease (MBD)

Target Disease

• Disease name: Marchiafava–Bignami disease (MBD)
• Category: Neurological disorder (toxic-metabolic demyelinating/necrotizing disease of the corpus callosum) (singer2023diagnosisandmanagement pages 1-2, liu2024clinicalanalysisof pages 1-2)

1) Disease Information

1.1 Overview (current understanding)

Marchiafava–Bignami disease (MBD) is a rare neurologic disorder characterized by demyelination and necrosis of the corpus callosum, sometimes extending into adjacent subcortical/extra-callosal white matter. It is most strongly associated with chronic alcohol use disorder and malnutrition, and often presents with nonspecific neuropsychiatric symptoms that can delay diagnosis. MRI (particularly DWI) enables antemortem diagnosis and earlier treatment. (singer2023diagnosisandmanagement pages 1-2, liu2024clinicalanalysisof pages 1-2, singer2023diagnosisandmanagement pages 4-6)

Example abstract-supported definition (direct quote): the 2023 review describes MBD as “characterized by… myelin degeneration and tissue necrosis… [with]… necrotic degeneration… in the corpus callosum.” (published 2023-06-30; URL: https://doi.org/10.15190/d.2023.7) (singer2023diagnosisandmanagement pages 1-2)

1.2 Key identifiers (OMIM/Orphanet/ICD/MeSH/MONDO)

Authoritative ontology identifiers (e.g., Orphanet, ICD-10/ICD-11, MeSH, MONDO) were not retrievable from the sources available in this tool run, so they cannot be confirmed here.

1.3 Synonyms and alternative names

• Marchiafava–Bignami disease (MBD) (singer2023diagnosisandmanagement pages 1-2, liu2024clinicalanalysisof pages 1-2)
• Primary degeneration of the corpus callosum (used in imaging-oriented literature) (li2021diversemrifindings pages 1-3)

1.4 Evidence type (patient-level vs aggregated)

Most MBD knowledge is derived from case reports/series and small retrospective cohorts, rather than randomized clinical trials. A 2024 paper synthesized 33 cases (3 institutional cases plus 30 published case reports) to summarize clinical characteristics. (published 2024-10; URL: https://doi.org/10.1186/s12883-024-03901-y) (liu2024clinicalanalysisof pages 1-2)

2) Etiology

2.1 Disease causal factors (current view)

The leading causal model is toxic–metabolic injury related to alcohol exposure and nutritional deficiency, particularly thiamine (vitamin B1) depletion, producing energy failure, cytotoxic edema, demyelination, and necrosis in myelin-rich callosal tissue. (singer2023diagnosisandmanagement pages 1-2, menrai2024anatypicalcase pages 1-2)

Direct quote (abstract): alcohol “leads to thiamine depletion and disrupts various metabolic pathways… [which] hinders myelin synthesis.” (Singer et al., 2023-06-30; https://doi.org/10.15190/d.2023.7) (singer2023diagnosisandmanagement pages 1-2)

2.2 Risk factors

Major risk factors include: - Chronic alcohol use disorder and malnutrition (liu2024clinicalanalysisof pages 1-2, singer2023diagnosisandmanagement pages 1-2) - Thiamine/B-complex vitamin deficiency (singer2023diagnosisandmanagement pages 1-2)

Non-alcoholic triggers/associations reported in reviews include diabetic ketoacidosis and osmolality shifts (“callosal myelinolysis”), post-bariatric malnutrition, sepsis, carbon monoxide poisoning, cerebral malaria, and sickle cell disease. (singer2023diagnosisandmanagement pages 2-4)

Recent aggregated data (2017–2023 case reports): “Most patients have a history of alcohol consumption or malnutrition.” (Liu et al., 2024-10; https://doi.org/10.1186/s12883-024-03901-y) (liu2024clinicalanalysisof pages 1-2)

2.3 Protective factors

No genetic or pharmacologic protective factors were identified in the retrieved evidence. Indirectly, adequate nutrition and alcohol abstinence are protective in the sense of removing major risk exposures. (singer2023diagnosisandmanagement pages 1-2)

2.4 Gene–environment interaction

No specific gene–environment interactions are established in the retrieved literature; one case report states the cause “may involve… genetic predisposition” but does not provide gene/variant evidence. (Conceição et al., 2024-11-06; https://doi.org/10.7759/cureus.73146) (conceicao2024marchiafavabignamidiseasea pages 1-3)

3) Phenotypes

3.1 Core phenotypes and frequency (human clinical evidence)

A 2024 retrospective synthesis of 33 cases (2017–2023 case reports plus 3 institutional cases) quantified phenotype frequencies as follows (published 2024-10; https://doi.org/10.1186/s12883-024-03901-y): (liu2024clinicalanalysisof pages 2-4) - Movement disorder/dyskinesia: 22/33 (66.7%) (e.g., ataxia, limb weakness) (liu2024clinicalanalysisof pages 2-4) - Speech disorders: 19/33 (57.6%) (e.g., dysarthria, aphasia) (liu2024clinicalanalysisof pages 2-4) - Consciousness disorders: 18/33 (54.5%) (e.g., coma, somnolence, agitation) (liu2024clinicalanalysisof pages 2-4) - Cognitive impairment: 15/33 (45.5%) (liu2024clinicalanalysisof pages 2-4) - Emotional/personality change: 10/33 (30.3%) (liu2024clinicalanalysisof pages 2-4) - Seizures: 4/33 (12.1%) (liu2024clinicalanalysisof pages 2-4)

3.2 Onset age, severity, progression

• Typical age/sex: primarily affects middle-aged men in aggregated data (liu2024clinicalanalysisof pages 1-2)
• Onset pattern: often acute or subacute (liu2024clinicalanalysisof pages 1-2)
• Temporal staging: acute/subacute/chronic presentations are described in recent clinical literature; acute cases can include confusion/aggression/seizures, with chronic cases including progressive dementia-like syndromes. (conceicao2024marchiafavabignamidiseasea pages 3-4)

Quantitative course distribution (33 cases): acute 18/33 (54.5%), subacute 7/33 (21.2%), chronic 8/33 (24.2%). (liu2024clinicalanalysisof pages 2-4)

3.3 Suggested HPO terms (examples)

(These are ontology suggestions; exact mappings should be verified against HPO.) - Altered level of consciousness (e.g., coma/somnolence): HP:0001259 (common umbrella; exact term selection depends on case detail) (liu2024clinicalanalysisof pages 2-4) - Ataxia: HP:0001251 (liu2024clinicalanalysisof pages 2-4) - Dysarthria: HP:0001260 (liu2024clinicalanalysisof pages 2-4) - Aphasia: HP:0002381 (liu2024clinicalanalysisof pages 2-4) - Cognitive impairment: HP:0100543 (liu2024clinicalanalysisof pages 2-4) - Seizures: HP:0001250 (liu2024clinicalanalysisof pages 2-4) - Apraxia: HP:0002186 (liu2024clinicalanalysisof pages 2-4) - Neuropsychiatric/behavioral abnormality (broad): consider HP:0000708 (behavior abnormality) and/or more specific terms based on presentation (liu2024clinicalanalysisof pages 2-4)

3.4 Quality of life impact

Formal QoL instruments (EQ-5D/SF-36) were not identified in the retrieved literature. However, severe cases can lead to prolonged dependency and persistent deficits (e.g., neurogenic bladder, disorientation), indicating substantial functional impact. (menrai2024anatypicalcase pages 1-2)

4) Genetic / Molecular Information

4.1 Causal genes and pathogenic variants

MBD is not established as a monogenic disease in the retrieved evidence, and no causal genes/variants or ClinVar-style variant assertions were identified.

4.2 Mechanistic molecular pathways (non-genetic)

Mechanistic framing emphasizes metabolic and oxidative injury in callosal white matter, including: - Thiamine depletion → impaired energy metabolism → cytotoxic edema (reflected by restricted diffusion/low ADC) → demyelination/necrosis (singer2023diagnosisandmanagement pages 4-6, singer2023diagnosisandmanagement pages 1-2)

Suggested GO biological process terms (examples; to validate in GO): - Myelination (GO:0042552) - Axon ensheathment (GO:0008366) - Response to oxidative stress (GO:0006979) - Regulation of inflammatory response (GO:0050727)

5) Environmental Information

5.1 Environmental/lifestyle factors

The dominant environmental/lifestyle drivers are: - Chronic heavy alcohol exposure (liu2024clinicalanalysisof pages 1-2, zhang2023clinicoradiologicsubtypesand pages 1-2) - Malnutrition / inadequate intake and associated vitamin deficiency (liu2024clinicalanalysisof pages 1-2)

A 2023 cohort described long drinking histories (12–29 years; ~200–250 mL/day of 40–50% liquor). (Zhang et al., 2023-10; https://doi.org/10.1038/s41598-023-45431-6) (zhang2023clinicoradiologicsubtypesand pages 1-2)

5.2 Infectious agents

Not a primary infectious disease; however, cerebral malaria is listed as a reported association/trigger in review literature. (singer2023diagnosisandmanagement pages 2-4)

6) Mechanism / Pathophysiology

6.1 Causal chain (integrated)

A clinically useful causal chain consistent with recent reviews and cohort imaging is: 1) Chronic alcohol use and/or malnutrition → thiamine depletion and metabolic disruption (singer2023diagnosisandmanagement pages 1-2) 2) Energy failure in myelin-rich callosal tracts → cytotoxic edema (restricted diffusion/low ADC on DWI) (singer2023diagnosisandmanagement pages 4-6, zhang2023clinicoradiologicsubtypesand pages 1-2) 3) Demyelination and necrosis within corpus callosum ± extracallosal white matter (singer2023diagnosisandmanagement pages 1-2, liu2024clinicalanalysisof pages 1-2) 4) Clinical syndrome: altered consciousness, dysarthria/aphasia, ataxia/weakness, cognitive and psychiatric changes, disconnection syndromes (liu2024clinicalanalysisof pages 2-4, singer2023diagnosisandmanagement pages 7-9)

6.2 Cell types (suggested CL terms)

Specific single-cell evidence was not found. Relevant cell types likely include: - Oligodendrocyte (CL:0000128) - Astrocyte (CL:0000127) - Microglial cell (CL:0000129)

This is consistent with demyelinating pathology described in review literature (e.g., demyelination, decreased oligodendrocytes). (singer2023diagnosisandmanagement pages 4-6)

7) Anatomical Structures Affected

7.1 Organ/tissue localization

• Primary: corpus callosum (white matter commissure) (liu2024clinicalanalysisof pages 1-2, singer2023diagnosisandmanagement pages 1-2)
• Common subregions: splenium is frequently affected in case syntheses; anterior two-thirds and other callosal segments can be involved (liu2024clinicalanalysisof pages 1-2, conceicao2024marchiafavabignamidiseasea pages 1-3)
• Secondary/extra-callosal involvement: hemispheric white matter and other brain regions can be involved; extracallosal involvement correlates with severity and can be a poor prognostic feature. (singer2023diagnosisandmanagement pages 1-2, liu2024clinicalanalysisof pages 1-2, zhang2023clinicoradiologicsubtypesand pages 1-2)

Suggested UBERON terms (examples; verify in Uberon): - Corpus callosum: UBERON:0001877 - Cerebral white matter: UBERON:0016549 (or alternative white-matter term depending on ontology version)

7.2 Imaging illustration (MRI)

A 2024 case report provides representative MRI findings: T2/FLAIR hyperintensity of the anterior two-thirds of the corpus callosum with restricted diffusion on DWI/ADC consistent with acute edema/demyelination. (Conceição et al., 2024-11-06; https://doi.org/10.7759/cureus.73146) (conceicao2024marchiafavabignamidiseasea media 16521e3e, conceicao2024marchiafavabignamidiseasea media 7c11b093, conceicao2024marchiafavabignamidiseasea media 8bf57d9d)

8) Temporal Development

8.1 Onset

Commonly acute or subacute, though chronic forms occur. (liu2024clinicalanalysisof pages 1-2)

8.2 Progression and staging

Clinical literature commonly describes acute/subacute/chronic courses; the 2024 case report summarizes stage-associated symptom patterns (acute confusion/seizures; subacute dysarthria/apraxia/ataxia; chronic global dementia/behavioral changes). (conceicao2024marchiafavabignamidiseasea pages 3-4)

9) Inheritance and Population

9.1 Inheritance

No Mendelian inheritance pattern is established; disease is best characterized as acquired/toxic-metabolic in the retrieved evidence.

9.2 Epidemiology

Population prevalence/incidence estimates were not identified in the retrieved sources. The 2023 review notes rarity and describes a historical compilation of ~250 cases before 2001. (singer2023diagnosisandmanagement pages 2-4)

10) Diagnostics

10.1 Imaging

• MRI is the diagnostic gold standard for demonstrating callosal lesions in MBD. (singer2023diagnosisandmanagement pages 1-2, conceicao2024marchiafavabignamidiseasea pages 3-4)
• DWI is emphasized for early lesion detection and shows restricted diffusion with low ADC, supporting acute cytotoxic edema. (singer2023diagnosisandmanagement pages 4-6, zhang2023clinicoradiologicsubtypesand pages 1-2)
• The “sandwich sign” (central callosal lesion with sparing of dorsal and ventral layers) is described as a hallmark imaging pattern in acute disease. (menrai2024anatypicalcase pages 2-3, cm2017theimportanceof pages 1-3)

10.2 Laboratory testing / biomarkers

No validated disease-specific biomarker panel is established; labs often reflect nutritional and alcohol-related abnormalities and are used to evaluate deficiencies and exclude mimics. A 2024 case report found macrocytic anemia, folate deficiency, mild hypoalbuminemia, and elevated GGT. (conceicao2024marchiafavabignamidiseasea pages 1-3)

10.3 Differential diagnosis

A 2023 review provides a broad differential including Wernicke encephalopathy, vitamin B12/folate deficiency, metabolic/toxic etiologies, central myelinolysis, MS, infection/encephalitis, tumors, and systemic organ failure syndromes. (Singer et al., 2023-06-30; https://doi.org/10.15190/d.2023.7) (singer2023diagnosisandmanagement pages 7-9)

11) Outcome / Prognosis

11.1 Prognostic factors

Poor outcome predictors emphasized in reviews and recent cases include: - Severe consciousness disturbance/low GCS (menrai2024anatypicalcase pages 1-2) - Extensive cerebral cortex or extracallosal involvement (singer2023diagnosisandmanagement pages 1-2, zhang2023clinicoradiologicsubtypesand pages 1-2) - Delayed treatment; earlier thiamine is associated with better outcomes in review literature (singer2023diagnosisandmanagement pages 7-9)

11.2 Quantitative outcome data from cohorts

• In a 2023 acute cohort (n=23), Heinrich Type A vs B differed in admission MoCA and extracallosal involvement, but authors concluded prognosis could still be favorable with combined treatment and lesions could resolve. (Zhang et al., 2023-10; https://doi.org/10.1038/s41598-023-45431-6) (zhang2023clinicoradiologicsubtypesand pages 1-2)
• In a 17-patient acute MRI cohort, neuropsychiatric sequelae were reported in 5 cases overall, with higher sequelae in the most focal diffusion subtype (Type III: 60%). (Li et al., accepted 2020-06-16, published 2021-07; https://doi.org/10.1177/0284185120943040) (li2021diversemrifindings pages 1-3)

11.3 Mortality statistic (from review literature)

A 2020 BMJ Case Reports review reports that MRI-enabled diagnosis and earlier thiamine treatment improved prognosis “from frequently fatal to a mortality of less than 8%,” and that thiamine administered within 14 days is associated with statistically better outcomes. (Kinsley et al., 2020-12; https://doi.org/10.1136/bcr-2020-238187) (singer2023diagnosisandmanagement pages 1-2)

12) Treatment

12.1 Core pharmacotherapy (real-world implementation)

There are no universally accepted treatment guidelines, but convergent expert consensus and practice patterns support: - Immediate high-dose parenteral thiamine and B-complex vitamin replacement as first-line therapy (singer2023diagnosisandmanagement pages 1-2, conceicao2024marchiafavabignamidiseasea pages 3-4) - Nutritional rehabilitation and alcohol cessation/withdrawal management (zhang2023clinicoradiologicsubtypesand pages 1-2) - Rehabilitation therapies (physical/occupational/speech as indicated) (menrai2024anatypicalcase pages 1-2)

Example thiamine dosing used in a 2023 cohort: IV thiamine 500 mg/day plus methylprednisolone pulse 500–1000 mg/day for 3–5 days, then oral prednisone and compound B vitamins, with follow-up oral B vitamins and alcohol withdrawal. (Zhang et al., 2023-10; https://doi.org/10.1038/s41598-023-45431-6) (zhang2023clinicoradiologicsubtypesand pages 1-2)

Example dosing in a 2024 case report: IV thiamine 500 mg three times daily for 3 days, then 250 mg IV daily for 5 days, then 100 mg orally daily, plus B6/B9/B12 and rehabilitation. (Conceição et al., 2024-11-06; https://doi.org/10.7759/cureus.73146) (conceicao2024marchiafavabignamidiseasea pages 3-4)

12.2 Corticosteroids (evidence status)

Corticosteroids are frequently co-administered to address edema/inflammation, but reviews emphasize heterogeneous evidence and confounding by simultaneous vitamin therapy; thiamine remains the most consistently recommended intervention. (singer2023diagnosisandmanagement pages 7-9, singer2023diagnosisandmanagement pages 4-6)

12.3 Suggested MAXO terms (examples)

(Verify exact MAXO identifiers in MAXO.) - Thiamine supplementation / vitamin B supplementation (zhang2023clinicoradiologicsubtypesand pages 1-2, conceicao2024marchiafavabignamidiseasea pages 3-4) - Corticosteroid therapy (zhang2023clinicoradiologicsubtypesand pages 1-2) - Nutritional rehabilitation (liu2024clinicalanalysisof pages 1-2) - Alcohol cessation counseling / substance use treatment (zhang2023clinicoradiologicsubtypesand pages 1-2) - Rehabilitation therapy (menrai2024anatypicalcase pages 1-2)

13) Prevention

Primary prevention is largely exposure-based: - Prevent chronic malnutrition and vitamin deficiency in high-risk populations (alcohol use disorder, poor intake, post-surgical malabsorption) (liu2024clinicalanalysisof pages 1-2) - Early empiric thiamine in suspected deficiency states (modelled after Wernicke-Korsakoff practice patterns in reviews) (singer2023diagnosisandmanagement pages 4-6)

Secondary prevention is essentially early recognition (MRI use in appropriate presentations) to prevent irreversible injury. (singer2023diagnosisandmanagement pages 1-2)

14) Other Species / Natural Disease

No naturally occurring MBD analogs in non-human species were identified in the retrieved evidence.

15) Model Organisms

No validated disease-specific animal models were identified in the retrieved evidence. Mechanistic hypotheses largely extrapolate from thiamine deficiency and alcohol neurotoxicity biology rather than MBD-specific models.

Recent Developments (2023–2024 highlight)

1) Clinico-radiologic subtyping with treatment response: a 2023 cohort (n=23) validated Heinrich Type A/B comparisons and reported complete clinico-radiologic recovery with combined therapy, emphasizing reversibility. (Zhang et al., 2023-10; https://doi.org/10.1038/s41598-023-45431-6) (zhang2023clinicoradiologicsubtypesand pages 1-2) 2) Updated aggregated phenotype frequencies and onset distributions: a 2024 synthesis of 33 cases quantified symptom frequencies and reinforced extracallosal lesion burden as a poor prognostic marker. (Liu et al., 2024-10; https://doi.org/10.1186/s12883-024-03901-y) (liu2024clinicalanalysisof pages 2-4)

Current Applications / Real-World Implementations

• Emergency and inpatient neurology: MRI (especially DWI) to distinguish MBD from stroke and other toxic-metabolic encephalopathies, followed by empiric high-dose thiamine and supportive care. (singer2023diagnosisandmanagement pages 1-2, conceicao2024marchiafavabignamidiseasea pages 1-3)
• Monitoring and prognosis: DWI lesion extent and extracallosal involvement used as practical indicators of severity and potential outcome. (zhang2023clinicoradiologicsubtypesand pages 1-2, liu2024clinicalanalysisof pages 1-2)

Clinical Trials (translation status)

No MBD-specific therapeutic trials were identified. One interventional trial relevant to corpus callosum demyelination is: - NCT06065670 (ClinicalTrials.gov): “Assessing Changes in Multi-parametric MRI in Patients With Acute Demyelinating Lesions Taking Clemastine Fumarate as a Myelin Repair Therapy” (UCSF). Status: Not yet recruiting; estimated start: 2026-09-15; Phase: 1/2; n≈44. The trial targets acute demyelinating lesions broadly (e.g., MS-related) with corpus callosum myelin MRI outcomes; MBD appears in condition taxonomy but the study is not clearly MBD-specific. URL (ClinicalTrials.gov): https://clinicaltrials.gov/study/NCT06065670 (NCT06065670 chunk 1, NCT06065670 chunk 4)

Summary Table (evidence-synthesized)

Table: This table summarizes clinically useful, literature-derived facts about Marchiafava-Bignami disease for a disease knowledge base, including phenotypes, MRI patterns, classifications, treatment, and prognosis. It prioritizes recent 2023–2024 evidence while incorporating key quantitative findings from small cohorts and case syntheses.

Notes on PMID requirement

Several key items above come from open-access journals and case reports where the PMID was not available in the retrieved text during this tool run; therefore, DOI/URL and publication dates are provided as stable identifiers instead. (singer2023diagnosisandmanagement pages 1-2, liu2024clinicalanalysisof pages 1-2, zhang2023clinicoradiologicsubtypesand pages 1-2)

References

1. (singer2023diagnosisandmanagement pages 1-2): Emad Singer, Kinal Bhatt, Adesh Prashad, Larri Rudman, Islam Gadelmoula, and George Michel. Diagnosis and management of marchiafava-bignami disease, a rare neurological complication of long-term alcohol abuse. Discoveries, 11:e168, Jun 2023. URL: https://doi.org/10.15190/d.2023.7, doi:10.15190/d.2023.7. This article has 11 citations.

2. (liu2024clinicalanalysisof pages 1-2): Cong Liu, Hualong Wang, Bingchuan Xie, Shujuan Tian, and Yan Ding. Clinical analysis of marchiafava-bignami disease. BMC Neurology, Oct 2024. URL: https://doi.org/10.1186/s12883-024-03901-y, doi:10.1186/s12883-024-03901-y. This article has 7 citations and is from a peer-reviewed journal.

3. (singer2023diagnosisandmanagement pages 4-6): Emad Singer, Kinal Bhatt, Adesh Prashad, Larri Rudman, Islam Gadelmoula, and George Michel. Diagnosis and management of marchiafava-bignami disease, a rare neurological complication of long-term alcohol abuse. Discoveries, 11:e168, Jun 2023. URL: https://doi.org/10.15190/d.2023.7, doi:10.15190/d.2023.7. This article has 11 citations.

4. (li2021diversemrifindings pages 1-3): Wei Li, Chao Ran, and Jun Ma. Diverse mri findings and clinical outcomes of acute marchiafava-bignami disease. Acta Radiologica, 62:904-908, Jul 2021. URL: https://doi.org/10.1177/0284185120943040, doi:10.1177/0284185120943040. This article has 11 citations and is from a peer-reviewed journal.

5. (menrai2024anatypicalcase pages 1-2): Devika Menrai, Shyam Kiran Gandam Venkata, Sudeep Chakravarthy Bhuram, and Sai Sruthi Bhuram. An atypical case of marchiafava-bignami disease in a young chronic alcoholic: challenges in diagnosis and prognosis. Cureus, Dec 2024. URL: https://doi.org/10.7759/cureus.75468, doi:10.7759/cureus.75468. This article has 1 citations.

6. (singer2023diagnosisandmanagement pages 2-4): Emad Singer, Kinal Bhatt, Adesh Prashad, Larri Rudman, Islam Gadelmoula, and George Michel. Diagnosis and management of marchiafava-bignami disease, a rare neurological complication of long-term alcohol abuse. Discoveries, 11:e168, Jun 2023. URL: https://doi.org/10.15190/d.2023.7, doi:10.15190/d.2023.7. This article has 11 citations.

7. (conceicao2024marchiafavabignamidiseasea pages 1-3): Paulo Conceição, Tânia Lopes, Vasco Abreu, and Ana Reinas. Marchiafava-bignami disease: a case report of a reversible cause of dementia. Cureus, Nov 2024. URL: https://doi.org/10.7759/cureus.73146, doi:10.7759/cureus.73146. This article has 0 citations.

8. (liu2024clinicalanalysisof pages 2-4): Cong Liu, Hualong Wang, Bingchuan Xie, Shujuan Tian, and Yan Ding. Clinical analysis of marchiafava-bignami disease. BMC Neurology, Oct 2024. URL: https://doi.org/10.1186/s12883-024-03901-y, doi:10.1186/s12883-024-03901-y. This article has 7 citations and is from a peer-reviewed journal.

9. (conceicao2024marchiafavabignamidiseasea pages 3-4): Paulo Conceição, Tânia Lopes, Vasco Abreu, and Ana Reinas. Marchiafava-bignami disease: a case report of a reversible cause of dementia. Cureus, Nov 2024. URL: https://doi.org/10.7759/cureus.73146, doi:10.7759/cureus.73146. This article has 0 citations.

10. (zhang2023clinicoradiologicsubtypesand pages 1-2): Yan-li Zhang, Chao Ran, Chao Xu, and Wei Li. Clinico-radiologic subtypes and therapeutic observation of acute marchiafava-bignami disease. Scientific Reports, Oct 2023. URL: https://doi.org/10.1038/s41598-023-45431-6, doi:10.1038/s41598-023-45431-6. This article has 8 citations and is from a peer-reviewed journal.

11. (singer2023diagnosisandmanagement pages 7-9): Emad Singer, Kinal Bhatt, Adesh Prashad, Larri Rudman, Islam Gadelmoula, and George Michel. Diagnosis and management of marchiafava-bignami disease, a rare neurological complication of long-term alcohol abuse. Discoveries, 11:e168, Jun 2023. URL: https://doi.org/10.15190/d.2023.7, doi:10.15190/d.2023.7. This article has 11 citations.

12. (conceicao2024marchiafavabignamidiseasea media 16521e3e): Paulo Conceição, Tânia Lopes, Vasco Abreu, and Ana Reinas. Marchiafava-bignami disease: a case report of a reversible cause of dementia. Cureus, Nov 2024. URL: https://doi.org/10.7759/cureus.73146, doi:10.7759/cureus.73146. This article has 0 citations.

13. (conceicao2024marchiafavabignamidiseasea media 7c11b093): Paulo Conceição, Tânia Lopes, Vasco Abreu, and Ana Reinas. Marchiafava-bignami disease: a case report of a reversible cause of dementia. Cureus, Nov 2024. URL: https://doi.org/10.7759/cureus.73146, doi:10.7759/cureus.73146. This article has 0 citations.

14. (conceicao2024marchiafavabignamidiseasea media 8bf57d9d): Paulo Conceição, Tânia Lopes, Vasco Abreu, and Ana Reinas. Marchiafava-bignami disease: a case report of a reversible cause of dementia. Cureus, Nov 2024. URL: https://doi.org/10.7759/cureus.73146, doi:10.7759/cureus.73146. This article has 0 citations.

15. (menrai2024anatypicalcase pages 2-3): Devika Menrai, Shyam Kiran Gandam Venkata, Sudeep Chakravarthy Bhuram, and Sai Sruthi Bhuram. An atypical case of marchiafava-bignami disease in a young chronic alcoholic: challenges in diagnosis and prognosis. Cureus, Dec 2024. URL: https://doi.org/10.7759/cureus.75468, doi:10.7759/cureus.75468. This article has 1 citations.

16. (cm2017theimportanceof pages 1-3): Pontes Cm, M. Cagy, R. Santos, and Soares Cn. The importance of brain mri in the diagnosis of marchiafava-bignami disease. Journal of Neurology and Neurological Disorders, Aug 2017. URL: https://doi.org/10.15744/2454-4981.3.201, doi:10.15744/2454-4981.3.201. This article has 1 citations.

17. (NCT06065670 chunk 1): Assessing Changes in Multi-parametric MRI in Patients With Acute Demyelinating Lesions Taking Clemastine Fumarate as a Myelin Repair Therapy. University of California, San Francisco. 2026. ClinicalTrials.gov Identifier: NCT06065670

18. (NCT06065670 chunk 4): Assessing Changes in Multi-parametric MRI in Patients With Acute Demyelinating Lesions Taking Clemastine Fumarate as a Myelin Repair Therapy. University of California, San Francisco. 2026. ClinicalTrials.gov Identifier: NCT06065670